文献速递糖尿病

跨祖先1型糖尿病多基因风险评分的开发与验证

Development and validation of a trans-ancestry polygenic risk score for type 1 diabetes.
PubMed 文献 · Diabetologia · 2026-03-07

研究利用PRS-CSx方法整合欧洲、东亚、非裔美国人和西班牙裔1型糖尿病全基因组关联研究数据(总病例29,469例),开发跨祖先多基因风险评分(TA-PS),并在加拿大蒙特利尔多祖先病例对照队列(总样本4,657例,非欧洲裔556例)中测试,在四个独立队列中验证。结果显示TA-PS的AUROC为0.89,显著高于GRS2x的0.85,且在90百分位切点下不同祖先的灵敏度更优,支持其用于人群筛查。

要点

  • TA-PS在蒙特利尔多祖先队列中AUROC为0.89,显著优于GRS2x的0.85。
  • 90百分位切点下TA-PS灵敏度:欧洲裔0.71,南亚裔0.77;GRS2x为非裔0.32、欧洲裔0.56。
  • TA-PS特异性略低于GRS2x但可接受(所有祖先≥0.83),结果在四个独立队列中验证。

核心结论

  • 开发了跨祖先PRS(TA-PS),其性能优于基于欧洲数据的GRS2x,并在不同祖先中提供可比预测,支持用于人群筛查。

研究设计与样本

  • 在加拿大蒙特利尔多祖先1型糖尿病病例对照队列(总样本4,657例,非欧洲裔556例)中测试性能,并在两个独立病例对照队列(CHOP-CAG和GRACE)及两个人群队列(All of Us和UK Biobank)中验证。

主要发现

  • 在蒙特利尔多祖先队列中,TA-PS的AUROC为0.89,显著高于GRS2x的0.85。
  • 在90百分位切点下,TA-PS在欧洲裔中灵敏度为0.71,南亚裔为0.77;GRS2x在非裔美国人中灵敏度为0.32,欧洲裔为0.56。
  • TA-PS的特异性略低于GRS2x,但在所有祖先中仍可接受(≥0.83)。
  • 结果在四个独立队列中得到验证。

关键数值与推荐

  • TA-PS在蒙特利尔多祖先队列中AUROC为0.89,GRS2x为0.85。
  • 90百分位切点下TA-PS灵敏度:欧洲裔0.71,南亚裔0.77;GRS2x灵敏度:非裔美国人0.32,欧洲裔0.56。
  • TA-PS特异性在所有祖先中≥0.83。

临床怎么用

  • TA-PS可用于跨祖先人群的1型糖尿病遗传风险筛查,识别高风险个体以进行自身抗体和代谢监测,避免诊断时酮症酸中毒并获取预防性治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The high heritability of type 1 diabetes has enabled the development of polygenic risk scores (PRSs) as disease risk screening tools. PRSs can identify individuals at the highest genetic risk in a population, who can benefit from autoantibody and metabolic surveillance, to avoid ketoacidosis at diagnosis and to access preventive therapies. However, PRSs for type 1 diabetes developed from European data perform less well in non-European ancestries. We aimed to develop a PRS with comparable performance among different ancestries. METHODS: Using the PRS-CSx method, and data from large European, East Asian, African American and Hispanic type 1 diabetes genome-wide association studies (Ntotal_cases=29,469), we developed a trans-ancestry PRS (TA-PS), combining a non-HLA component incorporating over a million variants with the HLA component of a published European PRS (GRS2x). We tested the performance of the PRS using area under the receiver operating curve (AUROC), sensitivity and specificity in a multi-ancestry type 1 diabetes case-control cohort (Ntotal=4657; Nnon-European=556) from Montreal, Canada. We validated our results in two independent type 1 diabetes case-control cohorts (Children's Hospital of Philadelphia, Center for Applied Genomics [CHOP-CAG] and Genetic Risk Assessment for Chinese Eaglet-T1D [GRACE]) and two population-based cohorts (All of Us and UK Biobank). RESULTS: In the multi-ancestry Montreal-based cohort, TA-PS showed an AUROC of 0.89 which was significantly higher than the respective measure obtained with GRS2x in the same population (AUROC of 0.85). We obtained better overall sensitivity at the 90th percentile cut-off using TA-PS (0.71 in Europeans, 0.77 in South Asians), compared with sensitivity of 0.32 in African Americans and 0.56 in Europeans using GRS2x. The specificity obtained using TA-PS was slightly lower than that of GRS2x, albeit still acceptable (≥0.83 across all ancestries). These results were validated in the four independent cohorts. CONCLUSIONS/INTERPRETATION: We developed a trans-ancestry PRS that outperformed the European-based GRS2x. Importantly, TA-PS provides a comparable prediction in various ancestries, which supports its use in population-wide screening programmes.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Jumentier B, Qu HQ, Lu T, et al. Development and validation of a trans-ancestry polygenic risk score for type 1 diabetes. Diabetologia. 2026. PMID: 41795035. doi:10.1007/s00125-026-06706-5

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。